TKI drugs like sorafenib, pazopanib, and lenvatinib act by targeting Raf kinase mutations such as the BRAFV600E mutation arising in nearly 25–45% of ATC patients, receptor tyrosine kinases associated with angiogenesis such as vascular endothelial growth factor receptor (VEGFR) 1 ‐2 and ‐3, platelet‐derived growth factor receptor (PDGFR)‐β, and receptor tyrosine kinases associated with tumor progression (Flt‐3, c‐kit), respectively [73]. Here, FLT3 is linked to neoplasm.